Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Express Scripts CEO Sees Transparency Law Consequences

This article was originally published in The Pink Sheet Daily

Executive Summary

PBMs are able to secure better prices from manufacturers without transparency, Paz says.

You may also be interested in...

PCMA To Continue To Fight D.C. PBM Transparency Law

D.C. lawmakers attempt to lift injunction by revising transparency bill to resemble legislation from Maine.

Express Scripts Sees Rapid Switching to Zocor

The success at switching patients to Zocor ahead of the availability of a generic demonstrates the success of PBMs in driving market share, CEO Paz says.

PCMA Challenges D.C.'s PBM "Transparency" Provision In Federal Court

The PBM association's arguments against Title II of D.C.'s "AccessRx Act of 2004" mirror those made in a similar case in Maine. PCMA contends that the law, which requires PBMs to disclose financial arrangements with drug manufacturers, is unconstitutional and preempted by ERISA.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts